GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that ...

Alliance News 5 March, 2024 | 11:03AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

ViiV Healthcare is a specialist HIV company majority owned by GSK, with Pfizer Inc and Shionogi & Co Ltd as shareholders. GSK is a Brentford, UK-based pharmaceutical maker.

Findings from a Phase One study, which were released by ViiV Healthcare at a conference on Tuesday, showed that an investigational formulation of cabotegravir, known as cabotegravir ultra long-acting, can be dosed at intervals of at least four months.

Data also showed that the intramuscular dosing of CAB-ULA has a safety and pharmacokinetic profile that supports a longer dose interval. According to GSK, these results are ViiV Healthcare's first step towards delivering ultra long-acting injectable HIV treatment and prevention medicines.

ViiV Healthcare is currently conducting a registrational study of CAB-ULA in 2024 to further evaluate its use for the prevention of HIV in adults.

GSK shares were trading 0.4% higher at 1,675.00 pence each in London on Tuesday morning.

By Holly Beveridge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
GSK PLC 1,636.00 GBX -0.91
Pfizer Inc 26.27 USD -0.19

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures